Department of Veterans Affairs, Office of Research and Development (VA)

Agency/Department

FLC Region

Security Lab

No

Address

810 Vermont Ave (NW)
Washington, DC 20420
United States

Want more information? Contact a representative below.

Laboratory Representative

Description

 

VA’s Research and Development program (VA Research), with its distinguished history of discovery and innovation dating back to 1925, today remains an essential part of VA’s efforts to ensure the health and wellbeing of our nation’s Veterans. The fundamental mission of VA Research is to advance the health and care of Veterans. It is part of the Veterans Health Administration, America’s largest integrated health care systems with over 1,700 sites of care, serving 8.3 million Veterans each year. With a state of-the-art electronic health record, VA Research is uniquely positioned to conduct pioneering research.

 

With the unique combination of accessible data, a national research setting with linked infrastructure, and a large research population, VA Research is renowned for conducting large-scale clinical trials and comparative effectiveness research. With more than 70 percent of VA researchers also providing care to patients, the program is poised to quickly move innovations and discoveries from the research setting to the care setting. Findings from clinical research, considered with findings from genomics and health services research, VA Research provides evidence-based information that can be used to enhance VA’s ability to provide personalized health care, care tailored to a specific patient’s circumstances. By giving VA providers such evidence-based information about an intervention’s effectiveness, the research helps guide providers as they consider various health care options and inform patients to participate in care decisions.

Mission

The Office of Research and Development (ORD) aspires to discover knowledge, develop VA researchers and health care leaders, and create innovations that advance health care for our Veterans and the Nation. ORD is headquartered in Washington, DC and has an estimated 3,000 investigators and 10,000 research staff located at 119 VA Medical Centers (VAMCs around the country. VA Research is an intramural research program that also embraces its close ties with academic affiliates, other federal agencies, nonprofit organizations, and private industry. By partnering with others who have common research interests, VA Research is able to leverage resources and expand the impact of federal research investments.

ORD consists of four research services that together form a cohesive whole to explore all phases of veterans' healthcare needs. Each Service oversees a number of world renowned research centers nationwide.

The Biomedical Laboratory Research & Development Service conducts research that explores basic biological or physiological principles in humans or animals but does not involve intact human beings. For example, it includes research on animal models and investigations of tissues, blood or other biologic specimens from humans

The Clinical Science Research and Development Service conducts research that focuses on intact human beings as the unit of examination. Examples include interventional and effectiveness studies, clinical, epidemiological and technological studies.

The Health Services Research and Development Service pursues research at the interface of health care systems, patients and health care outcomes. HSR&D underscores all aspects of VA health care; specifically quality, access, patient outcomes and health care costs.

The Rehabilitation Research & Development Service is dedicated to the well-being of America's veterans through a full spectrum of research: from approved rehabilitation research projects, through evaluation and technology transfer to final clinical application.

Each of these four services is headed by a director who is supervised by the Chief Research and Development Officer (CRADO), who in turn reports to the Deputy Under Secretary for Health for Policy and Services.

Technology Disciplines

Technologies
Displaying 1 - 10 of 292
 
Wearable diagnostic system for retinal disease
Wearable diagnostic system for retinal disease
A System and Method for Positioning and Supporting an Exercise Machine for use in a Hospital Bed (M-PACE)
A High Current, Radio Frequency Coupled Microstimulator for Autonomic Applications
A Surgically Implantable Urinary Incontinence Device
Acridone compounds
Acridone compounds
Activating extraction of demineralized bone matrix
Activation of quiescent stem cells
Acyl CoA:cholesterol acyltransferase (ACAT-2)

Pages

Facilities

No Facilities

Equipment

No Equipment

Programs

No Programs

Funds

No Funds

Publications

No Publications

Successes

No Successes

Licenses
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateJan 26, 2022

Systems and methods that combine an amplitude modulation spatial light modulator (SLM) with a phase modulating SLM in the same optical illumination system. The combination of the amplitude modulation SLM and the phase modulation SLM allows the optical illumination to compensate for the limitations of amplitude modulation SLM by using phase modulating SLM and conversely to compensate for the limitations of phase modulation SLM by using amplitude modulating SLM.

Dates:
Comments must be received on or before February 11, 2022.
Address:
Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420
For further information contact:

David Marks at 202-443-5609 or at david.marks2@va.gov.

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention because MicroLight3D submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateJan 07, 2022

NOTICE: VA Offer of Exclusive Patent and Know-How License to UTECH Products Inc.

BY THE: Department of Veterans Affairs, Office of Research and Development (VA)

ON: January 6, 2021

SUMMARY: Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to grant to UTECH Products Inc. DBA Endosoft LLC, 135 Broadway, Schenectady, NY 12350 an exclusive license to U.S. Patent Application No. 63/036,280 and PCT/US2021/036420, associated with VA Invention Disclosure number 2020-150 titled, “Methods and Systems for Determining an Object Map”, and associated Know-How, i.e. a software application useful for the diagnosis of polyps identified during colonoscopy.

TECH NAME: “Artificial Intelligence-Augmented Visualization with Real Time Histology Mapping of Colorectal Polyps”

ACTION: Intent

DATES: Comments must be received on or before Jan 21, 2022.

ADDRESS: Send comments to Mr. Kip Bodi, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (617) 390-4728 (this is not a toll-free number), Email: kip.bodi@va.gov

FOR FURTHER INFORMATION CONTACT: Send comments to Mr. Kip Bodi, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (617) 390-4728 (this is not a toll-free number), Email: kip.bodi@va.gov

SUPPLEMENTARY INFORMATION: The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as UTECH Products Inc. DBA Endosoft LLC has submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Dates:
Jan 6 - Jan 21, 2022
Address:
810 Vermont Ave., NW Washington, D.C. 20420
For further information contact:

Mr. Kip Bodi, Technology Transfer Specialist
Office of Research and Development
Email: kip.bodi@va.gov

Supplementary information:
Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateDec 21, 2021

Real-Time Histology of Colonic Polyps with Augmented Visualization
Termed real-time histology (RTH), the method is an in situ Computer-Aided Diagnostic (CADx) approach that increases the transparency and interpretability of results by generating an intuitive augmented visualization of predicted histology. Using deep learning models, polyps are first segmented into multiple regions, each of which are classified independently and then aggregated to generate a histology map along the polyp surface. The system encodes this spatial information with shades of red to represent high-confidence neoplastic assessments, shades of yellow to represent low-confidence assessments, and shades of green to represent high-confidence non-neoplastic assessments. This color-coded information provides an augmented visualization of polyp histologic prediction in real time, delivering an intuitive visual map for clinicians to quickly assess whether a polyp should be further investigated and removed.

Applications
U.S. Provisional Patent Application Serial No. 63/036,280 for “METHODS AND SYSTEMS FOR DETERMINING AN OBJECT MAP”, filed on June 8, 2020
Patent Cooperation Treaty (PCT) Application Serial No. PCT/US2021/36420 for “METHODS AND SYSTEMS FOR DETERMINING AN OBJECT MAP”, filed on June 8, 2021

Inventors
Satish K. Singh
Eladio Rodriguez-Diaz

Dates:
Comments must be received on or before Jan 6, 2022.
Address:
Department of Veterans Affairs, Office of Research and Development 810 Vermont Avenue, NW Washington, D.C. 20420
For further information contact:

Mr. Kip Bodi
Technology Transfer Specialist
Tel. 617-390-4728
Email: kip.bodi@va.gov

Supplementary information:
Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateOct 15, 2021

Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to grant to LucyDx, LLC, 651 N. Broad St., Ste. 205 #4847, Middletown, DE 19709, USA, an exclusive license to international patent filing application no. PCT/US2020/054781, associated with VA Invention Disclosure number 2019-434 titled, “DEVICES, SYSTEMS, AND METHODS FOR PERFORMING ELECTRORETINOGRAPHY”.

Dates:
Comments must be received by October 31st, 2021
Address:
Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420
For further information contact:

Send comments to Dr. Brandy Wade Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (470) 558-5486 (this is not a toll-free number), Email: brandy.wade@va.gov

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention to LucyDX, LLC. as they have submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateOct 04, 2021

Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to grant to SteroTherapeutics LLC, 3805 Old Easton Road Doylestown, Pennsylvania, 18902, USA, an exclusive license to international patent filing applicaton no. PCT/US2020/028445 (publication no. WO/2020/214,773), associated with VA Invention Disclosure number 2019-155 titled, “Galanin inhibitors for liver fibrosis treatment.”

Dates:
Comments must be received on or before October 22, 2021.
Address:
Send comments to Dr. Jenish Patel, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (937) 409-7993 (this is not a toll-free number), Email: Jenish.Patel@va.gov
For further information contact:

Dr. Jenish Patel, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (937) 409-7993 (this is not a toll-free number), Email: Jenish.Patel@va.gov

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the U.S. Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as SteroTherapeutics has submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateAug 26, 2021

Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to offer to Fillauer Companies, Inc., 210 Amnicola Highway, Chattanooga, TN 37406, an exclusive license to U.S. Patent Nos. 9,549,827; 10,105,243; 10,376,388; and U.S. Patent Application Serial No. 16/404,777, associated with VA Invention Disclosure number 10-083 titled, “Improvements to Passive Ankle-Foot Prosthesis Capable of Automatic Adaptation to Sloped Walking Surfaces”.

Dates:
Comments must be received on or before September 10, 2021.
Address:
Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), ryan.davis7@va.gov.
For further information contact:

Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), ryan.davis7@va.gov.

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as the license will comply with the requirement to submit a complete and sufficient application for a license prior to execution of a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateAug 19, 2021

The present invention provides methods of treating an auditory impairment associated with outer hair cells of the cochlea in a subject. The method may comprise administering to said subject an effective amount of a composition comprising, as an active agent, an oligonucleotide sequence having a portion of a mammalian telomere sequence so as to reduce the auditory impairment thereby treating the auditory impairment in the subject.

Dates:
Comments must be received by September 3, 2021
Address:
Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420
For further information contact:

Send comments to Dr. Lee A. Sylvers, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (813) 505-6989 (this is not a toll-free number), Email: lee.sylvers@va.gov

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention to Weinberg Medical Physics, Ltd. as they have submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateAug 19, 2021

A mask can comprise a covering material that is sufficiently sized to extend over a mouth and a
nose on a head of a wearer. The covering material can have an outer surface and an inner
surface. The covering material can define an opening therethrough. At least one transparent
membrane can be coupled to the covering material and cover the opening in the covering
material. The at least one transparent membrane can define a hole therethrough. An elongate
conduit can define an interior passage having a central axis. The elongate conduit can be
coupled to the at least one transparent membrane so that the central axis of the interior passage is
aligned with the hole. The mask can further comprise at least one securing element for securing
the mask to the head of the wearer.

Dates:
Comments must be received by September 3, 2021
Address:
Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420
For further information contact:

Send comments to Dr. Lee A. Sylvers, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (813) 505-6989 (this is not a toll-free number), Email: lee.sylvers@va.gov

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention to Dravon Medical, Inc. as they have submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateAug 16, 2021

Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to offer to Apex Foot Health Industries, 400 Frank W. Burr Blvd. Suite #240, Teaneck, NJ 07666, an exclusive license to VA’s rights in US Patent Nos. 10,292,452 and 10,779,612 and all foreign counterparts, associated with VA Invention Disclosure number 2015-060 titled, “Rocker Shoe Development Kit”.

Dates:
Comments must be received on or before August 31, 2021
Address:
Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), ryan.davis7@va.gov.
For further information contact:

Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), ryan.davis7@va.gov.

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as the license will comply with the requirement to submit a complete and sufficient application for a license prior to execution of a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateAug 16, 2021

Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to offer to ResQ Pharma, Inc., 2242 W. Harrison St., Ste. 201, Chicago, Illinois 60612, an exclusive license to VA’s rights in International Patent Application Nos. PCT/US2018/012623 and PCT/US2019/033997 and U.S. Patent Application Nos. 16/476,404 and 17/058,545 and all foreign counterparts, associated with VA Invention Disclosure numbers 2020-096 and 2020-147 titled, “Methods for Decreasing Injuries Associated with Intraoperative Hypotension” and “Lipid Emulsions and Uses Thereof”.

Dates:
Comments must be received on or before August 31, 2021.
Address:
Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), ryan.davis7@va.gov.
For further information contact:

Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), ryan.davis7@va.gov.

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as the license will comply with the requirement to submit a complete and sufficient application for a license prior to execution of a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry

Pages